versapenia 50 mg 30 tablets

Versapenia Tablets are indicated for the treatment of thrombocytopenia (low platelet count). They belong to the thrombopoietin receptor agonist class and contain the active ingredient eltrombopag olamine. The medication stimulates the bone marrow to increase platelet production, helping reduce the risk of bleeding.

It is used in the management of chronic immune thrombocytopenia (ITP) in both adults and children. It also supports the treatment of thrombocytopenia associated with chronic hepatitis C and severe aplastic anemia, providing an advanced therapeutic option under specialist medical supervision.

Versapenia Ingredients

Eltrombopag.

Versapenia Strengths

Film-coated tablets, 50 mg, pack containing 30 tablets.

Uses of Versapenia

Treatment of chronic immune thrombocytopenia (ITP).

Increasing platelet counts in patients with chronic hepatitis C to enable the initiation or continuation of interferon-based therapy.

Treatment of severe aplastic anemia in patients who have not responded adequately to first-line therapy.

Reducing the risk of serious bleeding associated with low platelet counts.

Versapenia Dosage

The usual starting dose for adults is 50 mg once daily. The physician may adjust the dose based on the patient's response and platelet count monitoring.

Take the tablet on an empty stomach, either one hour before or two hours after meals. Follow your physician's prescribed dosage schedule carefully.

Side Effects of Versapenia

Nausea, vomiting, or mild diarrhea.

Headache, fatigue, or muscle and joint pain.

Mild elevation of liver enzymes in some patients.

Contraindications of Versapenia

Do not use Versapenia if you are allergic to eltrombopag olamine or any of the product's ingredients.

Use with caution and under close medical supervision in patients with severe liver impairment or those at increased risk of venous or arterial thromboembolic events.

Versapenia Alternatives

Revolade.

Use During Pregnancy and Breastfeeding

The use of Versapenia during pregnancy is generally not recommended unless the expected benefit to the mother clearly outweighs the potential risk to the fetus, as determined by the treating physician.

Breastfeeding should be discontinued during treatment because there are insufficient data regarding the excretion of eltrombopag into human breast milk.

Women of childbearing potential should consult their physician before starting treatment and use effective contraception throughout therapy as recommended.

Storage Conditions

Store at room temperature below 30°C.

Keep in a dry place away from moisture and direct sunlight.

Store the tablets in their original, tightly closed package.

Keep out of the reach of children.